Literature DB >> 25409847

Osteochemonecrosis: an overview.

John Hellstein1.   

Abstract

Osteonecrosis of the jaw to a certain extent has been with us for many years. But recently the advent of various medications such as bisphosphonates, VEGF inhibitors, tyrosine kinase inhibitors and humanized antibodies to osteoclastic action have resulted in thousands of cases. While the bisphosphonates continue to be the most common medication associated with osteochemonecrosis antibodies such as denosumab which irreversibly act on osteoclastic action are also being reported. This narrative review will serve as an update with a focus on some of the histopathologic features discussed and reviewed. Perhaps even more uncommonly seen in past reports a discussion of features possibly observed while grossing specimens will be discussed. At the end of this report is hoped that the pathologist will have a better understanding of the historical features, clinical settings, gross examination features as well as histopathologic features associated with osteochemonecrosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25409847      PMCID: PMC4245410          DOI: 10.1007/s12105-014-0583-z

Source DB:  PubMed          Journal:  Head Neck Pathol        ISSN: 1936-055X


  74 in total

1.  Comprehensive review of bisphosphonate therapy: implications for the oral and maxillofacial surgery patient.

Authors:  Salvatore L Ruggiero; Eric R Carlson; Leon A Assael
Journal:  J Oral Maxillofac Surg       Date:  2009-05       Impact factor: 1.895

2.  Osteonecrosis of the jaw after zoledronic acid and denosumab treatment.

Authors:  Vittorio Fusco; Claudia Galassi; Alfredo Berruti; Libero Ciuffreda; Cinzia Ortega; Giovannino Ciccone; Alberto Angeli; Oscar Bertetto
Journal:  J Clin Oncol       Date:  2011-05-02       Impact factor: 44.544

3.  Response to - a commentary on "Suppurative osteomyelitis, bisphosphonate induced 1 osteonecrosis, osteoradionecrosis: a blinded histopathologic comparison and its 2 implications for the mechanism of each disease" by R.E. Marx and R. Tursun [Int. J. Oral. Maxillofac. Surg. 41 (3) (2012) 283-289].

Authors:  R E Marx; R Tursun
Journal:  Int J Oral Maxillofac Surg       Date:  2012-12-04       Impact factor: 2.789

4.  A commentary on "Suppurative osteomyelitis, bisphosphonate induced osteonecrosis, osteoradionecrosis: a blinded histopathologic comparison and its implications for the mechanism of each disease" by R.E. Marx and R. Tursun [Int. J. Oral Maxillofac. Surg. 41 (2012) 283-289].

Authors:  John R Kalmar
Journal:  Int J Oral Maxillofac Surg       Date:  2012-10-26       Impact factor: 2.789

5.  Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.

Authors:  Valentina Guarneri; David Miles; Nicholas Robert; Véronique Diéras; John Glaspy; Ian Smith; Christoph Thomssen; Laura Biganzoli; Tanya Taran; PierFranco Conte
Journal:  Breast Cancer Res Treat       Date:  2010-04-02       Impact factor: 4.872

6.  Suppurative osteomyelitis, bisphosphonate induced osteonecrosis, osteoradionecrosis: a blinded histopathologic comparison and its implications for the mechanism of each disease.

Authors:  R E Marx; R Tursun
Journal:  Int J Oral Maxillofac Surg       Date:  2012-01-11       Impact factor: 2.789

7.  Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy.

Authors:  Cesar A Migliorati; Mark M Schubert; Douglas E Peterson; Luis Marcelo Seneda
Journal:  Cancer       Date:  2005-07-01       Impact factor: 6.860

8.  The progress of the periodontal syndrome in the rice rat. I. Morphometric and autoradiographic studies.

Authors:  J E Gotcher; W S Jee
Journal:  J Periodontal Res       Date:  1981-05       Impact factor: 4.419

Review 9.  Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw.

Authors:  Matthias Troeltzsch; Timothy Woodlock; Stefanie Kriegelstein; Timm Steiner; Karl Messlinger; Markus Troeltzsch
Journal:  J Can Dent Assoc       Date:  2012       Impact factor: 1.316

10.  Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.

Authors:  Sundeep Khosla; David Burr; Jane Cauley; David W Dempster; Peter R Ebeling; Dieter Felsenberg; Robert F Gagel; Vincente Gilsanz; Theresa Guise; Sreenivas Koka; Laurie K McCauley; Joan McGowan; Marc D McKee; Suresh Mohla; David G Pendrys; Lawrence G Raisz; Salvatore L Ruggiero; David M Shafer; Lillian Shum; Stuart L Silverman; Catherine H Van Poznak; Nelson Watts; Sook-Bin Woo; Elizabeth Shane
Journal:  J Bone Miner Res       Date:  2007-10       Impact factor: 6.741

View more
  5 in total

1.  Orofacial manifestations of SAPHO syndrome: a systematic review of case reports.

Authors:  Clémence Ferreira-Vilaca; Leonor Costa Mendes; Sophie-Caroline Campana; Isabelle Bailleul-Forestier; Christine Audouin-Pajot; Rémi Esclassan; Thibault Canceill
Journal:  Clin Rheumatol       Date:  2020-05-09       Impact factor: 2.980

2.  Zoledronate treatment duration is linked to bisphosphonate-related osteonecrosis of the jaw prevalence in rice rats with generalized periodontitis.

Authors:  Jonathan G Messer; Jessica M Jiron; Jorge L Mendieta Calle; Evelyn J Castillo; Ronnie Israel; Ean G Phillips; Joshua F Yarrow; Catherine Van Poznak; Lakshmyya Kesavalu; Donald B Kimmel; J Ignacio Aguirre
Journal:  Oral Dis       Date:  2019-02-19       Impact factor: 3.511

3.  Odontogenic Head and Neck Region Infections Requiring Hospitalization: An 18-Month Retrospective Analysis.

Authors:  Ewa Zawiślak; Rafał Nowak
Journal:  Biomed Res Int       Date:  2021-01-18       Impact factor: 3.411

4.  Medication-Related Osteonecrosis of Jaws: A Low-Level Laser Therapy and Antimicrobial Photodynamic Therapy Case Approach.

Authors:  Mariana Comparotto Minamisako; Guilherme Henrique Ribeiro; Mariáh Luz Lisboa; Mabel Mariela Rodríguez Cordeiro; Liliane Janete Grando
Journal:  Case Rep Dent       Date:  2016-09-07

5.  Effect of S53P4 bioactive glass and low-level laser therapy on calvarial bone repair in rats submitted to zoledronic acid therapy.

Authors:  Caio Peres Bellato; Danilo Louzada de Oliveira; Marcus Vinicius Satoru Kasaya; David Moreira; Marcelo Augusto Cini; Patricia Pinto Saraiva; Jéssica Lemos Gulinelli; Pâmela Leticia Santos
Journal:  Acta Cir Bras       Date:  2021-07-09       Impact factor: 1.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.